CLEAR Outcomes Company Update Call: Detailed Results Discussion

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to CLEAR Outcomes Company Update Call: Detailed Results Discussion

Esperion Therapeutics (ESPR) to Buy at Jefferies ahead of ACC

February 24, 2023 11:34 AM EST

Jefferies upgraded Esperion Therapeutics (NASDAQ: ESPR) to a Buy rating (From Hold) and doubled the price target on the stock to $6.00 (From $12.00) following incrementally positive management comments heading into the CLEAR CV outcomes data at ACC on March 4th.

Jefferies analysts are confident ESPR should meet or beat the Street's 15% cardiovascular benefit "bar," but even... More